Medical device company Vitrolife AB (STO:VITR) announced on Friday the receipt of market approval for the time-lapse incubator EmbryoScope+ in the US, considered the world's third largest market measured in terms of number of IVF treatments.
EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for 15 patients. Vitrolife is a market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos.
With this approval, Vitrolife will be able to offer EmbryoScope+ to clinics in US.
Vitrolife develops, produces and markets medical devices for assisted reproduction.
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
Pulnovo Medical commences enrolment in PULSE-LHD IDE clinical trial
Implantica's RefluxStop receives US FDA approval
Sectra to provide Education Portal to Loyalist College for medical imaging training
Aqua Medical treats second type 2 diabetes patient in IDE trial of investigational PIMA procedure
Abbott and NACHC launch nationwide Food for Health initiative
Galmed reports positive preclinical results for Aramchol in prostate cancer
Galderma receives EU approval for Restylane Shaype facial shaping injectable